Fernandes, João PauloSilva, MarciaSousa, MargaridaBhikha, JaniMoreira, PaulaSilva, Isabel2025-03-122025-03-122024-10Fernandes JP, Silva M, Sousa M, Bhikha J, Moreira P, Silva I. Adverse events related to etonogestrel implant: an old but still current issue? In: 23rd ISoP Annual Meeting “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics”, Montreal (Canada), October 1-5, 2024. Drug Saf. 2024;47(12):1334.http://hdl.handle.net/10400.21/21662Introduction: In December 2019, in Portugal, a Direct Healthcare Professional Communication (DHPC) was approved regarding the subcutaneous implant of etonogestrel 68 mg. The genesis of this communication was based on reported cases of neurovascular injury and migration of the implant from the insertion site within the arm, or, in rare cases, into the pulmonary artery, possibly associated with deep or incorrect implant insertion. To minimize risks, the DHPC has introduced updates to the instructions for the insertion and removal of the implant. Aim/Objective: Our work aims to conduct a descriptive analysis of the number of Individual Case Safety Reports (ICSRs) received by the Portuguese National Pharmacovigilance System (SNF) following the DHPC, related to adverse events associated with the insertion and removal of the etonogestrel implant.engImplantEtonogestrelAdverse effectsconference poster